PT2581367E - Sais de mostarda de isofosforamida e seus análogos - Google Patents

Sais de mostarda de isofosforamida e seus análogos

Info

Publication number
PT2581367E
PT2581367E PT131500373T PT13150037T PT2581367E PT 2581367 E PT2581367 E PT 2581367E PT 131500373 T PT131500373 T PT 131500373T PT 13150037 T PT13150037 T PT 13150037T PT 2581367 E PT2581367 E PT 2581367E
Authority
PT
Portugal
Prior art keywords
analogs
salts
isophosphoramide mustard
isophosphoramide
mustard
Prior art date
Application number
PT131500373T
Other languages
English (en)
Inventor
C Amedio John
P Wallner Barbara
B Komarnitsky Philip
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2581367(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Publication of PT2581367E publication Critical patent/PT2581367E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT131500373T 2007-04-06 2008-04-04 Sais de mostarda de isofosforamida e seus análogos PT2581367E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92214807P 2007-04-06 2007-04-06
US92736307P 2007-05-02 2007-05-02
US93491407P 2007-06-15 2007-06-15
US123707P 2007-10-30 2007-10-30

Publications (1)

Publication Number Publication Date
PT2581367E true PT2581367E (pt) 2016-03-28

Family

ID=39387443

Family Applications (2)

Application Number Title Priority Date Filing Date
PT87272993T PT2155682E (pt) 2007-04-06 2008-04-04 Sais de mostarda de isofosforamida e análogos da mesma
PT131500373T PT2581367E (pt) 2007-04-06 2008-04-04 Sais de mostarda de isofosforamida e seus análogos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT87272993T PT2155682E (pt) 2007-04-06 2008-04-04 Sais de mostarda de isofosforamida e análogos da mesma

Country Status (22)

Country Link
US (2) US8604007B2 (pt)
EP (2) EP2155682B1 (pt)
JP (1) JP5659010B2 (pt)
KR (3) KR101505415B1 (pt)
CN (2) CN102942589B (pt)
AU (1) AU2008236684B2 (pt)
BR (1) BRPI0809999A2 (pt)
CA (1) CA2684747A1 (pt)
CY (1) CY1116596T1 (pt)
DK (2) DK2155682T3 (pt)
ES (1) ES2547302T3 (pt)
HU (1) HUE025949T2 (pt)
IL (2) IL201424A (pt)
MX (1) MX2009010820A (pt)
NZ (1) NZ580341A (pt)
PL (1) PL2155682T3 (pt)
PT (2) PT2155682E (pt)
RU (1) RU2527531C2 (pt)
SI (1) SI2155682T1 (pt)
TW (2) TWI501972B (pt)
WO (1) WO2008124097A2 (pt)
ZA (1) ZA200907722B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5336082B2 (ja) 2004-10-25 2013-11-06 デック−テク インコーポレイテッド 抗腫瘍剤としてのイソホスホルアミドマスタードの塩及びその類似物
US7964583B2 (en) * 2006-02-17 2011-06-21 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
EP2155682B1 (en) 2007-04-06 2015-06-24 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
US8664201B2 (en) * 2008-07-31 2014-03-04 Ziopharm Oncology, Inc. Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
JP5779106B2 (ja) * 2009-02-24 2015-09-16 デック−テック， インコーポレイテッド 抗腫瘍剤としての４−ヒドロペルオキシイホスファミドの錯体
WO2013116281A1 (en) * 2012-01-31 2013-08-08 Ziopharm Oncology, Inc. Combination therapy including isophosphoramide mustard, analogs, or salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU427945A1 (ru) 1972-07-24 1974-05-15 Институт элементоорганических соединений СПОСОБ ПОЛУЧЕНИЯа ПОЛИФТОРАЛКИЛЗАМЕЩЕННЫХБЕНЗИЛДИХЛОРФОСФАТОВ
JPS5159886A (pt) 1974-11-20 1976-05-25 Shionogi Seiyaku Kk
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US5091552A (en) * 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
EP0639186B1 (en) 1992-04-17 1999-06-23 Abbott Laboratories Taxol derivatives
US5468499A (en) * 1993-11-15 1995-11-21 Ohio State University Liposomes containing the salt of phosphoramide mustard and related compounds
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
EP1185276B1 (en) * 1999-05-24 2003-12-10 Southern Research Institute Isophosphoramide mustard analogs and use thereof
AR030188A1 (es) 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
CA2406160A1 (en) 2000-04-13 2001-10-25 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
CN1759115A (zh) 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
JP5336082B2 (ja) * 2004-10-25 2013-11-06 デック−テク インコーポレイテッド 抗腫瘍剤としてのイソホスホルアミドマスタードの塩及びその類似物
EP2155682B1 (en) 2007-04-06 2015-06-24 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof

Also Published As

Publication number Publication date
EP2581367A2 (en) 2013-04-17
TW200906842A (en) 2009-02-16
US20080255056A1 (en) 2008-10-16
US9340563B2 (en) 2016-05-17
KR101505415B1 (ko) 2015-03-25
ZA200907722B (en) 2010-11-24
BRPI0809999A2 (pt) 2014-10-14
DK2581367T3 (en) 2016-03-14
JP5659010B2 (ja) 2015-01-28
TWI501972B (zh) 2015-10-01
PT2155682E (pt) 2015-10-15
KR101604244B1 (ko) 2016-03-17
DK2155682T3 (en) 2015-09-21
SI2155682T1 (sl) 2015-11-30
ES2547302T3 (es) 2015-10-05
MX2009010820A (es) 2010-03-18
KR20150139620A (ko) 2015-12-11
IL201424A0 (en) 2010-05-31
RU2527531C2 (ru) 2014-09-10
US20140194377A1 (en) 2014-07-10
JP2010523571A (ja) 2010-07-15
AU2008236684A1 (en) 2008-10-16
CY1116596T1 (el) 2017-03-15
WO2008124097A3 (en) 2008-12-24
CA2684747A1 (en) 2008-10-16
WO2008124097A2 (en) 2008-10-16
EP2581367B1 (en) 2015-12-30
EP2155682B1 (en) 2015-06-24
EP2581367A3 (en) 2013-07-03
CN102942589A (zh) 2013-02-27
IL223353A (en) 2016-02-29
TW201406772A (zh) 2014-02-16
KR20090130098A (ko) 2009-12-17
EP2155682A2 (en) 2010-02-24
NZ580341A (en) 2012-06-29
AU2008236684B2 (en) 2013-04-18
IL223353A0 (en) 2013-02-03
CN101679265B (zh) 2014-10-29
KR20130041391A (ko) 2013-04-24
IL201424A (en) 2016-02-29
RU2009140904A (ru) 2011-05-20
US8604007B2 (en) 2013-12-10
CN101679265A (zh) 2010-03-24
PL2155682T3 (pl) 2015-12-31
HUE025949T2 (en) 2016-05-30
TWI490226B (zh) 2015-07-01
CN102942589B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
EP2150109A4 (en) PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
ZA201006386B (en) Preparation of desulphurisation materials
EP2408755A4 (en) COMPOUNDS FIXED AT PSMA AND ITS USE
SG10201400957UA (en) Antiviral Compounds And Uses Thereof
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
IL223353A0 (en) Salts of isophosphoramide mustard and analogs thereof
IL248077A0 (en) Formulations, salts and polymers of transnorsertraline and their uses
HK1160925A1 (zh) 組織蛋白酶 的用途
ZA201100878B (en) Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
PL2493496T3 (pl) Zastosowanie GSTP1
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
HK1131039A1 (en) Pharmaceutical use of sophoricoside
IL210956A0 (en) Methionine analogs and methods of using same
GB201114396D0 (en) Location of basesation
PL2346485T3 (pl) Stosowanie betainy
GB0911709D0 (en) Stoma bridge
ZA200810632B (en) Derivativs and analogs of N-ethylquinolones and N-ethylazaquinolones
GB0706347D0 (en) Purification of salts
PL383760A1 (pl) Nowe zastosowanie undekan-2-olu
PL383759A1 (pl) Nowe zastosowanie undekan-2-olu
PL383758A1 (pl) Nowe zastosowanie undekan-2-onu
GB0705204D0 (en) Uses of (S)-clenbuterol
HU0800656D0 (en) Effective use of tea-composition
HU0900647D0 (en) Salts of 7-nitroindoline derivatives and use thereof